Company: BLCO
Filing Date: 2025-02-19
Form Type: 10-K
Source: 0001860742-25-000004
Chunk: 399

Company: Bausch & Lomb Corp
Filing Date: 2025-02-19
Form: 10-K
Item: Item 1A
Chunk 399
---
: (i) approximately 1,800,000 OPG PSUs with a weighted-average grant date fair value of $17.20 per RSU, (ii) approximately 800,000 TSR PSUs with an average grant date fair value of $21.21 per RSU and (iii) approximately 400,000 Organic Revenue Growth PSUs with a weighted-average grant date fair value of $16.09 per RSU.As of December 31, 2024, the total remaining unrecognized compensation expense related to non-vested performance-based RSUs amounted to $60 million, which will be amortized over the weighted-average remaining requisite service period of approximately 2.1 years. A maximum of approximately 10,800,000 common shares could be issued upon vesting of the performance-based RSUs outstanding as of December 31, 2024. There were no performance-based RSUs that vested during 2024 and 2023. In addition, while Bausch + Lomb did not grant performance-based RSUs during 2022, certain Bausch + Lomb employees continued to participate in BHC’s performance-based RSUs granted prior to May 5, 2022. As of December 31, 2024, the total remaining unrecognized compensation expense related to BHC non-vested performance-based RSUs was $0.14.ACCUMULATED OTHER COMPREHENSIVE LOSSAccumulated other comprehensive loss consists of:(in millions)December 31, 2024December 31, 2023Foreign currency translation adjustment$(1,358)$(1,217)Pension adjustment, net of tax(27)(28)$(1,385)$(1,245)Income taxes are not provided for foreign currency translation adjustments arising on the translation of Bausch + Lomb’s operations having a functional currency other than the U.S. dollar, except to the extent of translation adjustments related to Bausch + Lomb’s retained earnings for foreign jurisdictions in which Bausch + Lomb is not considered to be permanently reinvested.15.OTHER EXPENSE, NETOther expense, net for the years 2024, 2023 and 2022 consist of:(in millions)202420232022Asset impairments$5 $— $1 Restructuring, integration and separation costs26 44 14 Gain on sale of assets(5)— — Litigation and other matters5 3 1 Acquired in-process research and